Partnerships for Antibody Expression
Our connections enable you to shape a project to your needs, and only work with best-in-class solutions.
We have a singular focus at evitria – transient antibody expression in CHO. However, we work with a network of trusted partners, each with specific expertise. Whatever the shape of your project, evitria can support you.
Our expert network
Our connections enable you to shape a project to your needs, and only work with best-in-class solutions
If you are a service provider or technology licensor interested in partnering with evitria to enhance antibody development workflows, please get in touch with our business development team to explore how we can work with you in the future.
Therapeutic workflow
Screening & lead selection
- Phage Display screening
- Antibody engineering,
de-immunization, and humanization - Lead identification
Transient expression
- High-quality transient expression at evitria
- Purification by protein A/G/L and SEC
- Suitable for in vivo studies
- Option: afucosylation using GlymaxX® from ProBioGen
Characterization
- Bioconjugation
- Functional assays
- Developability assessments
- Cell line development and clinical/commercial manufacturing
CMC
- Stable cell line development
- Process Development
- GMP production for Phase I/II
Screening & Lead Selection
Phage Display screening
Antibody engineering, de-immunization & humanization
Lead identification
Transient expression
High-quality transient expression
Purification by protein A/G/L and SEC
Suitable for in vivo studies
Afucosylation using GlymaxX® from ProBioGen
Characterisation
Bioconjugation
Functional assays
Developability assessments
Cell line development and clinical/commercial manufacturing
CMC
Stable cell line development
Process Development
GMP production for Phase I/II
Selected partners
Atlas Antibodies
As part of Atlas Antibodies, evitria gains access to expanded resources and expertise, delivering even greater value to researchers. This collaboration combines Atlas Antibodies’ deep experience in producing highly validated research antibodies with evitria’s proficiency in custom recombinant antibody expression service.
Atlas Antibodies partners with evitria to support rapid R&D screening and selection through their extensive catalog of over 25,000 antibody constructs covering the human proteome. Their highly characterized and validated mono- and polyclonal antibodies provide researchers with reliable, off-the-shelf solutions for efficient research and development.
Lonza
Lonza is a leading company with expertise in fields like small molecules, biologics, and CGTs. Supporting services for both GMP and non-GMP applications, Lonza is a sought-after partner both in clinical and production settings, with several innovative techniques in their portfolio.
With Lonza’s bYlok® bispecific pairing technology, for instance, it is possible to considerably increase efficiency in the production of bispecific antibodies – tools that are gaining more and more attention in biomedical and biopharmaceutical research.
Rapid Novor
Rapid Novor helps researchers decode immunity so they can rapidly and effortlessly develop diagnostics, therapies, reagents, and treatments. Through antibody discovery and antibody sequencing services.
Rapid Novor have empowered thousands of researchers. The innovative next generation protein sequencing technology they have developed has the potential to unlock countless discoveries for human health. Their technology relies on mass spectrometry and advanced bioinformatics that delivers the correct sequence every time – this means you can confidently sequence and recombinantly express mAbs starting only with a small sample of protein from any species.
ProBioGen
ProBioGen is a renowned, Berlin-based Contract Development and Manufacturing Organization (CDMO), which operates on an international scale. They offer proprietary innovative technologies for optimized biopharmaceutical manufacturing and analysis.
ProBioGen’s service focus is on cell line engineering, process development, and GMP manufacturing of biopharmaceutical active ingredients and vaccines for clients in biotech and pharma. ProBioGen has been operational for more than 25 years.
Integral Molecular
With expertise in antibodies and complex targets, Integral Molecular has developed technologies that have enabled hundreds of companies worldwide working in research, drug discovery, and vaccine development. Their Membrane Proteome Array™ (MPA) is the industry-leading specificity testing platform for targeted biotherapeutics, including antibodies, CAR-T cells, ADCs, and others.
This cell-based protein array can quickly and affordably identify any off-targets your molecule may interact with— and it’s the only platform to screen exclusively on biologically relevant proteins in whole, unfixed cells. The MPA provides essential specificity data at the lead selection stage, and the MPA+IND service includes the necessary rigor and support for regulatory submissions.
RoukenBio
RoukenBio partners with biotherapeutic innovators worldwide, offering in vitro drug discovery services across human immunology, bioanalytical methods, cell line engineering, and bioassay development. They support research from early discovery to GMP-ready potency assays, focusing on areas like immuno-oncology and inflammation. RoukenBio also develops custom solutions, including their IndEx-2 inducible cell line platform, to replicate disease states and advance therapeutic projects.
As a partner of evitria, RoukenBio offers comprehensive antibody characterization services, from antigen binding studies to functional assays. They provide SPR assessments to measure binding affinities and kinetics, as well as cell-based assays to evaluate antibody effector functions. RoukenBio also specializes in custom solutions for complex antibodies, such as bispecifics, multi-specifics, and checkpoint inhibitors, helping to advance innovative therapeutic development.
